USA – Revvity, a leading science-based solutions company, has entered into a distribution agreement with SCIEX, a global leader in life sciences analytical technologies.
This partnership will integrate SCIEX’s cutting-edge mass spectrometry instruments with Revvity’s NeoBase 2 and NeoLSD reagents, advancing mass spectrometry-based newborn screening solutions to help identify a range of rare diseases in infants.
Mass spectrometry plays a crucial role in expanded newborn screening, providing an effective means to identify rare but treatable conditions such as lysosomal storage disorders and amino acid disorders.
In recent years, the use of mass spectrometry for newborn screening has grown significantly, and with this collaboration, Revvity and SCIEX aim to enhance the precision and robustness of these analyses.
The NeoBase 2 and NeoLSD MSMS reagent kits from Revvity will be combined with SCIEX’s mass spectrometers to improve the accuracy of newborn disease screenings.
Revvity’s NeoBase 2 non-derivatized MSMS kit is used to measure more than 50 analytes, including markers for X-linked adrenoleukodystrophy and adenosine deaminase severe combined immunodeficiency.
The firm’s NeoLSD MSMS kit is used to screen for lysosomal storage disorders, Gaucher disease, Niemann-Pick A/B disease, Pompe disease, Krabbe disease, Fabry disease, and MPS I disease. Both use dried blood spot samples.
As a science-based solutions company, Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech, diagnostic labs, academia and government agencies.
Transforming diagnostic precision
Petra Furu, Revvity’s General Manager for Reproductive Health, emphasized the significance of the agreement, stating, “Revvity is committed to advancing newborn screening and helping give babies a better start in life.
“This capability will provide our customers with the best options for their expanded screening programs by combining precise instrumentation with groundbreaking reagents.”
The collaboration between Revvity and SCIEX has already shown promising results. In a recent quarter, Revvity and SCIEX’s partnership improved the accuracy of mass spectrometry-based newborn screening, particularly for rare disorders.
By combining SCIEX’s mass spectrometry technology with Revvity’s reagent kits, laboratories are now able to identify disease variants more efficiently, enhancing the early detection of life-threatening conditions.
A leap forward in clinical genomics
The collaboration between Revvity and SCIEX reflects the growing importance of genomics in clinical diagnostics.
“As a company, Revvity aims to impact health across the lifespan. Our purpose is to expand the boundaries of human potential through science,” said Prahlad Singh, President and CEO of Revvity.
“We are uniquely positioned to accelerate breakthrough solutions, from preclinical research to disease diagnosis and treatment.”
The partnership also aligns with Revvity’s broader mission to offer science-based solutions that improve lives globally.
The company, which emerged from PerkinElmer, Inc., focuses on providing end-to-end expertise across life sciences, diagnostics, and healthcare, emphasizing innovation in diagnostics to support better clinical outcomes.
